Nutrition 21, Inc., a developer and marketer of nutritional supplements that help consumers manage blood sugar levels, improve cardiovascular health, enhance memory and address chronic joint pain today announced the newest addition to its portfolio of wellness brands: PRESCRIPTIX(TM).

The PRESCRIPTIX product line, comprised of three separate products, provides consumers a safe and more natural option by delivering clinical drug study levels of specific nutrients to enhance bone density, heart, and joint health.

    --  PRESCRIPTIX-OP  promotes bone density with clinical study doses of
        calcium and Vitamin D3;
   
    --  PRESCRIPTIX-CP  promotes heart health via clinical study doses of CoQ10;

    --  PRESCRIPTIX-JP supports joint health with clinical doses of glucosamine
        and chondroitin.

PRESCRIPTIX(TM) delivers the nutrients without a prescription via an innovative, two-step fusion caplet delivery system. The line contains key nutrients that do not have the side effects evident in many prescription medications. The new product line began shipping mid-June to more than 6000 Walgreens stores nationwide.

In addition to providing key clinical dose nutrients, the innovative PRESCRIPTIX(TM) delivery system offers a second advantage: a system formulated to enhance the efficient transmittal of the nutrients, and their benefits, to the body. The breakthrough, two-step fusion caplet system centers around a single dose comprised of two caplets which act as companions to one another: the first caplet contains the clinical dosages of nutrients; the second caplet contains a proprietary "smart" nutrient mix formulated to enhance and maximize the beneficial effects of the first caplet.

"This revolutionary product line offers consumers affordable, innovative alternatives to their bone density, heart and joint health support regimens," said Dean DiMaria, senior vice president-marketing, Nutrition 21. "The combination of delivering clinical study strength nutrients without a prescription and the innovation of our two-step fusion caplet delivery system is yet one more example of Nutrition 21's solid track record of creating innovative products known to continually offer best-in-class science with top quality ingredients. We are excited about the promise that PRESCRIPTIX brings to helping Americans achieve their goals of living longer, healthier and happier lives."

About PRESCRIPTIX-OP(TM)

The National Osteoporosis Foundation reports that by 2010, approximately 12 million people over the age of 50 are expected to have osteoporosis and another 40 million to have low bone mass. Women, in particular, may lose between 35 and 50 percent of their bone density as they age. There are two key defenses people can employ to support bone health - 1.) maintain bone density and 2.) retain bone mass. PRESCRIPTIX-OP provides clinical drug study levels of calcium and vitamin D3 - two nutrients integral to maintaining and protecting bone density - to help promote bone mass retention, maintain and retain bone density, and support calcium replenishment.

About PRESCRIPTIX-CP(TM)

It is estimated that one in three Americans have one or more types of cardiovascular disease. Two of the most prevalent conditions associated with this class of disease are high blood pressure (hypertension) and coronary heart disease. PRESCRIPTIX-CP provides clinical study dosages of Coenzyme Q10 - an essential energy nutrient that has been found to be in low levels in people with heart disorders - to support long term cardiovascular health.

About PRESCRIPTIX-JP(TM)

Nearly one-third of Americans suffer from chronic joint pain which affects people at any age and at any activity level. If not properly treated, chronic joint pain typically gets progressively worse and can lead to arthritis or other related conditions. PRESCRIPTIX-JP provides clinical study doses of glucosamine and chondroitin - two essential building blocks for healthy joints - to enhance joint mobility and flexibility and to improve joint function and comfort.

The PRESCRIPTIX line of supplements is now available in the vitamin aisle exclusively at Walgreens stores nationwide. For more information, visit http://www.nutrition21.com and www.PRESCRIPTIX.net.

About Nutrition 21

Nutrition 21, Inc., headquartered in Purchase, NY, is a nutritional bioscience company and the maker of chromium picolinate-based and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. Nutrition 21 holds more than 30 patents for nutrition products and uses. Nutrition 21's portfolio of health and wellness products include: Iceland Health Chromax(R), Iceland Health Advanced Memory Formula(TM), Diabetes Essentials, Iceland Health(R) Maximum Strength Omega-3 and Iceland Health(R) Joint Relief. The company also manufactures private label supplements and ingredients for third parties. Nutrition 21 distributes its products nationally through more than 29,000 major food, drug and super center stores throughout the United States and internationally. For more information please visit http://www.nutrition21.com.

Safe Harbor Provision

This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the Company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including its Form 10-K/A for the year ended June 30, 2008. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.